Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules – PharmiWeb.com

Related Articles:

• The Phase 1/2 CDNF topline results February 25, 2020       Neurotrophic factors are naturally occuring proteins that help to keep neurons alive, provide a supportive environment, and encourage growth. For a long time, researchers have been exploring methods of utilising the power of neurotrophic factors in regenerative strategies for neurodegenerative conditions, like Parkinson’s. Today, the biotech firm Herantis Pharma announced topline results of their Phase 1/2 clinical…
• World’s first human CDNF clinical trial for Parkinson’s disease December 17, 2020 Industry experts share the in-depth results of the TreatER project – a European Union-funded project which aims to deliver an innovative treatment for Parkinson’s disease Funded by the EU Horizon 2020 research and innovation programme, the four-year TreatER project, which is now coming to a close, has united 11 public and private sector partners from five European countries to help…
• Herantis Announces New Program to Develop Non-Invasive CDNF for Parkinson’s Treatment July 10, 2018 Herantis Pharma is launching a development program for non-invasive cerebral dopamine neurotrophic factor (CDNF) as a treatment candidate for patients with Parkinson’s disease, the company recently announced. Currently, the investigational treatment needs to be administered directly into the brain using an implanted delivery system suited for Parkinson’s patients. Under the new program, Herantis will seek new methods of delivering the therapy to…
• Patient Treatment Completed in Phase 1/2 Trial Testing Therapy Candidate CDNF in Parkinson’s Disease January 3, 2020 Patient treatment has been completed in a Phase 1/2 clinical trial testing cerebral dopamine neurotrophic factor (CDNF) for Parkinson’s disease, Herantis Pharma has announced. The trial (NCT03295786) is testing the safety and tolerability of CDNF in 17 patients with advanced Parkinson’s disease. Of these patients, 15 completed the main study and will advance into a six-month extension study where they…
• Herantis Creates Video to Show How Its Parkinson’s Therapy Works April 9, 2018 Herantis Pharma has created an educational video about the way its Parkinson’s treatment CDNF works. The explainer comes as the company has begun recruiting patients for a Phase 1/2 clinical trial (NCT03295786) of the potential therapy. Hallmarks of Parkinson’s include damage to dopamine-producing nerve cells in a brain area called the substantia nigra, toxic accumulation of alpha-synuclein protein clumps in nerve cells, and chronic brain inflammation.…
• Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules - BioSpace December 17, 2020 Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules  BioSpace
• CDNF Safe in Advanced Parkinson’s, Trial Results Show February 27, 2020 Treatment with cerebral dopamine neurotrophic factor (CDNF), developed by Herantis Pharma, was safe and well-tolerated among patients with advanced-stage Parkinson’s disease, according to topline results from a Phase1/2 clinical trial. The therapy also showed promise in measures of dopaminergic function in some patients. CDNF is based on a protein naturally found in the blood and cerebrospinal fluid (CSF), the liquid…
• Herantis’s Parkinson’s Therapy Passes Preliminary Trial Safety Evaluation February 20, 2018 An independent review board has found Herantis Pharma’s Parkinson’s therapy safe, paving the way for a Phase 1/2 clinical trial in Sweden to continue. The board based its decision on the safety results seen in the first few patients treated with cerebral dopamine neurotrophic factor, or CDNF, at Karolinska University Hospital in Stockholm. Its findings mean Herantis can recruit patients at two other study sites — Helsinki University Hospital…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Herantis Pharma Is Recruiting Patients for Clinical Trial of CDNF as Parkinson’s Treatment October 2, 2017 Herantis Pharma has started the first clinical trial of cerebral dopamine neurotrophic factor (CDNF) as a potential treatment for Parkinson’s disease. The first patient in the Phase 1/2 clinical trial has enrolled at the Karolinska University Hospital in Stockholm. The study will also involve another hospital in Sweden and one in Finland. Herantis is developing CDNF as a treatment for both Parkinson’s…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• ‘On Chip’ Blood-Brain Barrier Model Paves Way for Personalized Therapy, Study Suggests June 18, 2019 Using stem cells, researchers have recreated the complexity of the blood-brain barrier (BBB) — a critical protective brain structure — in a chip roughly the size of an AA battery. This personalized BBB experimental model, which combines stem cell research with Emulate’s Organ-Chip technology, will allow scientists to better understand how the barrier works while also providing a novel way to investigate…
• Herantis Announces Non-Invasive Treatment Plan of CDNF July 12, 2018 Herantis Pharma has announced the initiation of a 'non-invasive' CDNF (cerebral dopamine neurotrophic factor) development programme to broaden the application of CDNF in treating Parkinson's. Naturally present in the human blood circulation and cerebrospinal fluid, CDNF is a potent neuroprotective factor that promotes neuronal survival. In preclinical proof-of-concept studies CDNF has demonstrated beneficial effects in Parkinson's alleviating both motor and…
• Herantis Announces Non-Invasive Treatment Plan of CDNF July 12, 2018 Herantis Pharma has announced the initiation of a 'non-invasive' CDNF (cerebral dopamine neurotrophic factor) development programme to broaden the application of CDNF in treating Parkinson's. Naturally present in the human blood circulation and cerebrospinal fluid, CDNF is a potent neuroprotective factor that promotes neuronal survival. In preclinical proof-of-concept studies CDNF has demonstrated beneficial effects in Parkinson's alleviating both motor and…
• Effect of cerebral dopamine neurotrophic factor on endogenous neural progenitor cell migration in a rat model of Parkinson's disease. April 9, 2019 Related ArticlesEffect of cerebral dopamine neurotrophic factor on endogenous neural progenitor cell migration in a rat model of Parkinson's disease. EXCLI J. 2019;18:139-153 Authors: Nasrolahi A, Mahmoudi J, Karimipour M, Akbarzadeh A, Sadigh-Eteghad S, Salehi R, Farajdokht F, Farhoudi M Abstract This study investigated the ability of intra-subventricular zone (SVZ) administration of cerebral dopamine neurotrophic factor (CDNF) on neural progenitor…
• Predictors of Penetration-Aspiration in Parkinson's Disease Patients With Dysphagia: A Retrospective Analysis. April 4, 2019 Related ArticlesPredictors of Penetration-Aspiration in Parkinson's Disease Patients With Dysphagia: A Retrospective Analysis. Ann Otol Rhinol Laryngol. 2019 Apr 02;:3489419841398 Authors: Gaeckle M, Domahs F, Kartmann A, Tomandl B, Frank U Abstract OBJECTIVE:: Penetration-aspiration is considered the most severe sign of dysphagia, with aspiration pneumonia as one of its consequences. More than half of Parkinson's disease (PD) patients suffer from…
• Bayer doubles down on Parkinson’s? December 10, 2020 # # # # News today of two biotech companies merging did not cause much of a ripple in the media, but the wider implications of the move are rather significant for Parkinson’s. Today it was announced that Brain Neurotherapy Bio (BNB) is going to merge with Asklepios Biopharmaceutical (aka AskBio). BNB are currently clinically testing a GDNF gene therapy…
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Cerebral Dopamine Neurotrophic Factor Diffuses Around the Brainstem and Does Not Undergo Anterograde Transport After Injection to the Substantia Nigra. June 28, 2019 Cerebral Dopamine Neurotrophic Factor Diffuses Around the Brainstem and Does Not Undergo Anterograde Transport After Injection to the Substantia Nigra. Front Neurosci. 2019;13:590 Authors: Albert K, Renko JM, Mätlik K, Airavaara M, Voutilainen MH Abstract Cerebral dopamine neurotrophic factor (CDNF) has shown therapeutic potential in rodent and non-human primate models of Parkinson's disease by protecting the dopamine neurons from degeneration…
• Herantis Pharma begins Recruitment for CDNF Trial March 5, 2018 Herantis Pharma Plc's first clinical study for people with Parkinson's with the company's investigational product CDNF has proceeded to its first CDNF safety assessment study.  CDNF is a novel drug candidate for the treatment of neurodegenerative diseases including Parkinson's. CDNF is a protein present in the body's circulatory system with neuroprotective and neurorestorative properties. It is patented internationally by Herantis. Recruitment…
• Herantis Pharma begins Recruitment for CDNF Trial March 5, 2018 Herantis Pharma Plc's first clinical study for people with Parkinson's with the company's investigational product CDNF has proceeded to its first CDNF safety assessment study.  CDNF is a novel drug candidate for the treatment of neurodegenerative diseases including Parkinson's. CDNF is a protein present in the body's circulatory system with neuroprotective and neurorestorative properties. It is patented internationally by Herantis. Recruitment…
• Increased Serum Levels of Mesencephalic Astrocyte-Derived Neurotrophic Factor in Subjects With Parkinson's Disease. September 27, 2019 Related ArticlesIncreased Serum Levels of Mesencephalic Astrocyte-Derived Neurotrophic Factor in Subjects With Parkinson's Disease. Front Neurosci. 2019;13:929 Authors: Galli E, Planken A, Kadastik-Eerme L, Saarma M, Taba P, Lindholm P Abstract Background: Mesencephalic astrocyte-derived neurotrophic factor (MANF) and cerebral dopamine neurotrophic factor (CDNF) promote the survival of midbrain dopamine neurons in animal models of Parkinson's disease (PD). However, little is…